Sugammadex Sodium

PreclinicalSmall molecule

KKorea University Anam Hospital

Sugammadex Sodium is one of 2 small molecule programs targeting Neostigmine. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeostigmineCompleted

NeostigminePreclinical

Completed

Competition

Competitive Landscape

2 competitors in Neostigmine

#DrugCompanyPhaseTrials

Neuromuscular Blocking Agents

UUniversity of Maryland, Baltimore

Phase 3

1 2

Sugammadex Sodium

KKorea University Anam Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Gastric Cancer1 trial

Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient

Completed·KKorea University Anam Hospital·Phase 3·NCT03196791·196 enrolled

Bronchoscopy1 trial

Clinical Application Value of Remazolam Combined With Sugammadex Sodium in Anesthesia for Endotracheal Surgery Under Bronchoscopy

Completed·ZZhejiang Cancer Hospital·Phase 4·NCT05468671·34 enrolled

Neostigmine1 trial

Comparing Reversal With Neostigmine and Sugammadex in Paediatric

Completed·UUniversiti Sains Malaysia·N/A·NCT03137290·80 enrolled

COVID-191 trial

Postoperative Sugammadex After COVID-19

Unknown status·KKorea University Ansan Hospital·Phase 4·NCT05817019·300 enrolled

Complication1 trial

Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery and Complications

Completed·UUniversity Health Network, Toronto·Phase 4·NCT03679611·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Sugammadex Sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sugammadex Sodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sugammadex Sodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Korea University Anam Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: KKorea University Anam Hospital

Sugammadex Sodium

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Gastric Cancer1 trial

Bronchoscopy1 trial

Neostigmine1 trial

COVID-191 trial

Complication1 trial

References

Drug Info

Quick Facts

Related News